Xyrem (Sodium Oxybate) Patent Expiration, LOE Window & CMS Spending

Xyrem (Sodium Oxybate) by Jazz Pharmaceuticals: FDA Orange Book LOE 2033-09-15, 0 AB generics, $109.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJazz Pharmaceuticals
FDA Application & PathwayN021196 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-09-15
Orange Book Patents (*PED Extensions)13 patents (6 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$109.7M
2024 Medicare Part D Spend$70.3M
2024 Medicaid Spend$39.4M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 23.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.